Table 2.
Univariate and Multivariate Cox regression analysis for clinical events
| Univariate | Multivariate | |||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age | 1.04 (1.01–1.06) | 0.001 | 1.04 (1.01–1.08) | 0.018 |
| NYHA | 1.16 (0.87–1.54) | 0.310 | ||
| Sex | 1.44 (1.08–1.93) | 0.013 | 1.87 (1.07–3.27) | 0.027 |
| Smoking | 1.36 (0.98–1.89) | 0.062 | 1.47 (0.88–2.47) | 0.144 |
| BMI | 1.04 (1.00-1.08) | 0.036 | 1.00 (0.95–1.06) | 0.947 |
| Atrial fibrillation | 1.62 (1.20–2.18) | 0.002 | 0.92 (0.52–1.62) | 0.765 |
| Hypertension | 0.92 (0.66–1.28) | 0.630 | ||
| Chronic kidney disease | 1.44 (0.96–2.15) | 0.076 | 1.13 (0.60–2.12) | 0.704 |
| Hyperlipidemia | 1.08 (0.80–1.45) | 0.610 | ||
| CHD | 0.91 (0.68–1.22) | 0.521 | ||
| Diabetes | 1.45 (1.09–1.92) | 0.011 | 1.67 (1.07–2.61) | 0.024 |
| LDL | 1.07 (0.91–1.27) | 0.409 | ||
| Total cholesterol | 0.94 (0.83–1.06) | 0.315 | ||
| eGFR | 0.99(0.98-1.00) | 0.001 | 0.99 (0.98-1.00) | 0.132 |
| C-reactive protein | 1.03 (1.01–1.06) | 0.010 | 1.04 (0.99–1.07) | 0.056 |
| NT-proBNP | 1.00 (1.00–1.00) | 0.001 | 1.00 (1.00–1.00) | 0.014 |
| LVEF | 0.96 (0.93–0.99) | 0.007 | 1.01 (0.96–1.05) | 0.736 |
| LAVI | 1.03 (1.00-1.05) | 0.028 | 1.04 (0.99–1.11) | 0.097 |
| e’ | 0.87 (0.76–0.99) | 0.047 | 0.86 (0.72–1.03) | 0.110 |
| E/e’ | 1.06 (1.01–1.11) | 0.030 | 1.04 (0.97–1.12) | 0.212 |
| PASP | 1.01 (1.00-1.03) | 0.100 | ||
| LVEDD | 1.02 (1.00-1.05) | 0.059 | 0.98 (0.93–1.03) | 0.558 |
| Beta-blockers | 0.89 (0.67–1.19) | 0.445 | ||
| ACE + ARB | 0.73 (0.55–0.97) | 0.032 | 0.63 (0.39–0.99) | 0.048 |
| Diuretic | 0.93 (0.70–1.24) | 0.619 | ||
| MCRA | 0.99 (0.74–1.34) | 0.968 | ||
| Statins | 0.74 (0.52–1.06) | 0.099 | 0.59 (0.32–1.08) | 0.089 |
| Calcium channel blockers | 0.73 (0.53–1.01) | 0.054 | 0.80 (0.49–1.32) | 0.382 |
| Anticoagulant | 1.28 (0.89–1.85) | 0.180 | ||
| SHR > 0.99 | 2.57 (1.93–3.44) | < 0.001 | 2.34 (1.49–3.67) | < 0.001 |
NYHA: New York heart association; BMI: body mass index; CHD: coronary heart disease; LDL: low-density lipoprotein; eGFR: estimated glomerular filtration rate; NT-proBNP: N-terminal pro–B-type natriuretic peptide; LVEF: left ventricular ejection fractions; LAVI: left atrial volume index; e’: peak LV velocity; E/e’: mean septal velocity; PASP: pulmonary artery systolic pressure; LVEDD: left ventricular end-diastolic dimension; ACE + ARB: angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; MCRA: mineralocorticoid receptor antagonist; SHR: stress hyperglycemia ratio; HR: hazard ratio; CI: confidence interval